(NASDAQ:TMDX) trading higher today on Cowen analyst raise to $35.00

TransMedics Group (NASDAQ:TMDX – Get Rating) had its target price raised by research analysts at Cowen from $28.00 to $35.00 in a research note issued to investors on Wednesday, The Fly reports. Cowen’s target price would suggest a potential upside of 60.04% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group upped their price target on TransMedics Group from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, March 17th. Morgan Stanley lowered their price target on TransMedics Group from $22.00 to $15.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $20.00 to $12.00 in a report on Thursday, February 24th. Zacks Investment Research cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Finally, Canaccord Genuity Group increased their target price on TransMedics Group from $38.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, March 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $31.29.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.